Brief: Longboard Pharmaceuticals Announces Initiation Of First-In-Human Phase 1 Clinical Study Of Lp659 In Adult Healthy Volunteers
29/11/2023 15:56
Longboard Pharmaceuticals Inc LBPH.O :
* LONGBOARD PHARMACEUTICALS ANNOUNCES INITIATION OF
FIRST-IN-HUMAN
PHASE 1 CLINICAL STUDY OF LP659 IN ADULT HEALTHY VOLUNTEERS
* LONGBOARD PHARMACEUTICALS INC - INITIATED SINGLE-ASCENDING
DOSE
(SAD) PHASE 1 CLINICAL STUDY EVALUATING LP659
Source text for Eikon: ID:nBwbYrHJva
Further company coverage: LBPH.O
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions